FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					01	Occilo	11 30(11)	or tire	IIIVCStillClit	Comp	party Act	01 1340								
1. Name and Address of Reporting Person* Burton Karen L						2. Issuer Name and Ticker or Trading Symbol STERIS Ltd [STE]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify					
(Last) (First) (Middle) L						3. Date of Earliest Transaction (Month/Day/Year) 03/28/2019									X Officer (give title Offier (specify below) VP, Controller & CAO					
(Street) DUBLIN L2 2				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	X Form filed by One Reporting Person Form filed by More than One Reportin						
(City)	(S	tate)	(Zip)												Persoi	n				
		Tab	le I - No			_			quired, D	Disp					/ Owned	k				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						Execution Date		n Date	e, Transaction Code (Instr.		5)			4 and Securi Benefi Owned Repor		es ally Following d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(D)		rice	Transaction(s) (Instr. 3 and 4)					
Ordinary	Shares			<u> </u>	3/2019				A		8,404			(2)		04 ⁽¹⁾		D		
		7							uired, Dis s, options						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title a Amount Securitie Underlyi Derivativ (Instr. 3 a	of s ng re Sec	2	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amo or Num of Sha							
Employee Stock Option (right to buy)	\$36.09	03/28/2019			A		3,800		(3)	05/	/31/2021	Ordinary Shares	3,8	300	(3)	3,800		D		
Employee Stock Option (right to buy)	\$29.94	03/28/2019			A		3,700		(4)	05/	/30/2022	Ordinary Shares	3,7	700	(4)	3,700		D		
Employee Stock Option (right to buy)	\$45.34	03/28/2019			A		4,040		(5)	05/	/31/2023	Ordinary Shares	4,0)40	(5)	4,040		D		
Employee Stock Option (right to buy)	\$53.52	03/28/2019			A		3,400		(6)	05/	/30/2024	Ordinary Shares	3,4	100	(6)	3,400		D		
Employee Stock Option (right to buy)	\$66.15	03/28/2019			A		2,852		(7)	05/	/28/2025	Ordinary Shares	2,8	352	(7)	2,852		D		
Employee Stock Option (right to buy)	\$69.72	03/28/2019			A		2,600		(8)	06/	/01/2026	Ordinary Shares	2,6	500	(8)	2,600		D		
Employee Stock Option (right to buy)	\$77.07	03/28/2019			A		4,000		(9)	05/	/30/2027	Ordinary Shares	4,0	000	(9)	4,000		D		
Employee Stock Option (right to	\$114.22	03/28/2019			A		7,900		(10)	05/	/31/2028	Ordinary Shares	7,9	000	(10)	7,900		D		

- 1. 7,016 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 764 on May 28, 2019; 700 on October 1, 2019; 1,220 on June 1, 2020; 3,000 on June 1, 2021; and 1,332 on May 31, 2022.
- 2. Represents ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS") received by the reporting person pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received shares of STERIS in an amount equal to the number of the reporting person's cancelled shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"). The reporting person's STERIS shares are subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS.
- 3. This option to purchase 3,800 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,800 Old STERIS ordinary shares for \$36.09 per share, subject to the same terms and conditions as the original Old STERIS stock option.
- 4. This option to purchase 3,700 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,700 Old STERIS ordinary shares for \$29.94 per share, subject to the same terms and conditions as the original Old STERIS stock option.
- 5. This option to purchase 4,040 Old STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 4,040 Old STERIS ordinary shares for \$45.34 per share, subject to the same terms and conditions as the original Old STERIS stock option.
- 6. This option to purchase 3,400 STERIS ordinary shares, which is fully vested, was received under the Scheme in exchange for an option to purchase 3,400 Old STERIS ordinary shares for \$53.52 per share, subject to the same terms and conditions as the original Old STERIS stock option.
- 7. This option becomes exercisable as follows: 713 on May 28, 2016, 713 on May 30, 2017, 713 on May 29, 2018 and 713 on May 28, 2019. This option was received under the Scheme in exchange for an option to purchase 2,852 STERIS ordinary shares for \$66.15 per share, subject to the same terms and conditions as the original Old STERIS stock option.
- 8. This option becomes exercisable as follows: 650 on June 1, 2017; 650 on June 1, 2018; 650 on June 3, 2019 and 650 on June 1, 2020. This option was received under the Scheme in exchange for an option to purchase 2,600 STERIS ordinary shares for \$69.72 per share, subject to the same terms and conditions as the original Old STERIS stock option.
- 9. This option becomes exercisable as follows: 1,000 on May 30, 2018; 1,000 on May 30, 2019; 1,000 on June 1, 2020 and 1,000 on June 1, 2021. This option was received under the Scheme in exchange for an option to purchase 4,000 STERIS ordinary shares for \$77.07 per share, subject to the same terms and conditions as the original Old STERIS stock option.
- 10. This option becomes exercisable as follows: 1,975 on May 31, 2019; 1,975 on June 1, 2020; 1,975 on June 1, 2021 and 1,975 on May 31, 2022. This option was received under the Scheme in exchange for an option to purchase 7.900 STERIS ordinary shares for \$114.22 per share, subject to the same terms and conditions as the original Old STERIS stock option.

Remarks:

/s/ Ronald E. Snyder,
Authorized Representative 03/28/2019
under Power of Attorney

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.